Median CR duration was 13.5 months, >24 months in 17% of the patients, and 18-30.5 months in the four patients with trisomy 8. CR duration was not associated with P15 methylation status or karyotype. Median overall survival was 20 months.
Summary
This prospective phase II study is the first to assess feasibility and efficacy of maintenance 5-azacytidine for older patients with high-risk MDS, CMML and MDS-AML syndromes in complete remission (CR) after induction chemotherapy. Sixty patients were enrolled and treated by standard induction chemotherapy. Patients that reached CR started maintenance therapy with subcutaneous azacytidine, 5/28 days until relapse. Promoter-methylation status of CDKN2B (P15), e-cadherin and hypermethylated in cancer 1 was examined pre-induction, in CR and 6, 12 and 24 months post CR. Twenty-four (40%) patients achieved complete remission after induction chemotherapy and 23 started maintenance treatment with azacytidine.
Median CR duration was 13.5 months, >24 months in 17% of the patients, and 18-30.5 months in the four patients with trisomy 8. CR duration was not associated with P15 methylation status or karyotype. Median overall survival was 20 months.
Hypermethylation of E-cadherin was significantly associated with low CR rate, early relapse, and short OS (P=0.003). 5-azacytidine treatment in a dose of 60 mg/m 2 was well tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 9.5 and 30% of the cycles, respectively, while hemoglobin levels increased during treatment.
5-azacytidine treatment is safe, feasible and may be of benefit in a subset of patients. Several studies show that around 50% (41-56%) of such patients reach a complete remission (CR). However, CR durations are short with almost no long-term survivors (Hast et al, 2003; Ganser et al, 2000; Kantarjian et al, 2006; Hofmann et al, 2007; Wattel et al, 1997) and standard consolidation chemotherapy is not associated with prolonged CR (Hast et al, 2003; Ganser et al, 2000; Hofmann et al, 2007; Wattel et al, 1997; Kantarjian et al, 2006) . The dismal prognosis for these patients lead to the search for other treatment regimens, where demethylating therapy is the most promising. In 2002, a randomized study comparing 5-azacytidine (azacytidine) to best supportive care only, reported prolonged time to the composite endpoint leukemic transformation or death in the azacytidine treated group (Silverman et al, 2002) . Also decitabine, another hypomethylating agent, had showed to be effective in MDS (Lübbert et al, 2001 ). This led us to hypothesize that maintenance treatment with azacytidine for patients in CR after induction chemotherapy might prolong time to relapse and survival. Azacytidine was initially used in high-doses for the treatment of patients with AML but was abandoned in favour for other agents due to severe gastrointestinal side effects and prolonged myelotoxicity (O'Dwyer & Maslak, 2008) . In lower doses, however, azacytidine was later shown to cause DNA demethylation by irreversible inhibition of DNA methyl transferases (Singal & Grinder, 2009; Esteller, 2008; Grønbaek et al, 2008) . The exact mechanisms of action in vivo are not known but it is clear that it can cause hypomethylation and re-expression of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   5 previously silenced genes as well as induction of apoptosis and immunomodulation (Guo et al, 2006; Berg et al, 2007; Schmeltz et al, 2005; Khan et al, 2008 ; Sánchez-Abarca et al, 2010). Genes previously known to be frequently methylated in MDS include CDKN2B (P15), E-cadherin (CDH) and Hypermethylated in Cancer 1 (HIC).
Promoter-methylation of these genes has also been reported to be associated with poor prognosis and leukemic transformation of MDS (Aggerholm et al, 2006; Tien et al, 2001; Christiansen et al, 2003) . We recently reported a strong association between promoter-methylation of CDH or of more than one of these three genes and failure to induction chemotherapy (Grövdal et al, 2007) . This study was designed to assess the feasibility and efficacy of long-term maintenance treatment with azacytidine in a cohort of elderly patients with high-risk MDS and AML following MDS in CR after conventional induction chemotherapy. System (IPSS), were eligible for the protocol (Jaffe et al, 2001; Greenberg et al, 1997) . Patients should not be eligible for AML-like induction chemotherapy followed by intensive consolidation courses and allogeneic stem cell transplantation, but should be considered to tolerate at least one cycle of standard induction chemotherapy. The study was approved by ethical committees and medical product agencies of the participating Nordic countries. All patients gave their written 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Grövdal et al, 2007; Jädersten et al, 2005) . Bone marrow cellularity was assessed on bone marrow biopsies and the percentage of blasts in bone marrow smears was determined by counting 500 cells in representative areas. Cytogenetic analyzes were performed locally only at enrolment, using standard techniques and patients were classified according to the IPSS into good, intermediate, or poor prognostic subgroups (Greenberg et al, 1997) . The criteria for CR were <5% bone marrow blasts, stable haemoglobin >100 g/L, WBC >1.5 x 10 9 with normal differential count and platelets >100 x 10 9
Materials and methods

Patients
. Persistent dysplastic features were allowed.
Study design
Induction chemotherapy consisted of a DA regimen: daunorubicin 60 mg/m 2 i. Further reduction of the azacytidine dose was also allowed to avoid severe as previously described (Grövdal et al, 2007; Nilsson et al, 2002) . Cells were stored as pellet at -80°C. Genomic DNA was isolated from MNC and CD34+ cells using the QiAmp DNA mini kit (Qiagen) according to manufacturer's guidelines. Bone marrow sampled in CR and during follow up frequently rendered an insufficient CD34+ yield, and methylation analyzes were therefore consequently performed on un-separated MNC, after first confirming a strong correlation between methylation results in CD34+
and MNC on the pre-induction samples (P<0.001) (Grövdal et al, 2007) . The amount of DNA obtained was measured by spectrophotometer (ND-100, Nano-Drop Technologies). DNA was further modified by sodium bisulfite as previously described (Grövdal et al, 2007; Zeschnigk et al, 1997) .
Polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE)
PCR specific for bisulfite-reacted P15, CDH and HIC promoters was carried out as previously described (Aggerholm et al, 2006; Grövdal et al, 2007) . Primer polyacrylamide -70% denaturant/12% polyacrylamide gradient gel. A fully methylated control (SssI) and an unmethylated control (peripheral blood lymphocytes) were also loaded to each gel. Gels were run at 160 V for 270 minutes in 1 x Tris acetate/EDTA buffer kept at a constant temperature specific for each gene examined as previously described (Aggerholm et al, 2006; Grövdal et al, 2007) . After the electrophoresis the gels were stained in Tris acetate/EDTA buffer containing ethidium bromide (2 mg/mL) and photographed under UV transillumination. Samples were scored as methylated when bands were present on the gels below the band corresponding to the unmethylated control (Aggerholm et al, 2006; Cremonesi et al, 1997) .
Pyrosequencing
In a fraction of samples, the DGGE results for P15 (N=29) and CDH (N=19) were compared in a blinded way to methylation analysis by pyrosequencing according to a previously described method with a congruence of 80% and 84% respectively (Tost et al, 2007; Geli et al, 2008) . In this article, DGGE results are used when referring to methylation status data. 
Statistics
Median haemoglobin levels during azacytidine maintenance were compared using
Wilcoxon signed-rank test. Survival analyzes were performed by the Kaplan-Meyer method and compared using the Log Rank test. The size of the material did not allow for an extended multivariate analyzes to be performed. All statistical calculations were carried out using SPSS 15.0 software for windows (SPSS Inc, Chicago, IL, USA). CR data and methylation status before treatment has previously been reported (Grövdal et al, 2007) . Of 24 patients (40%) who achieved CR, one underwent allogeneic stem cell transplantation and was taken off study, and 23 patients (median age 70 years, range 62-76) started maintenance therapy with azacytidine. Ten patients had MDS (RAEB-1 (1) or RAEB-2 (9)), 10 patients had AML, and 3 CMML-2 with >10% blasts. (Table I) .
Results
Patients
Feasibility and safety of azacytidine maintenance treatment
In case of grade 3 or 4 cytopenia or severe adverse event after azacytidine, the subsequent course was delayed with one week. However, according to protocol, a maintained interval between azacytidine courses was prioritized to dose and consequently, the protocol was amended when 3 of the first 5 patients treated with patients respectively (Table II) . However, only 22% (grade 3) and 8% (grade 4) of the total number of given courses were associated with neutropenia of this magnitude.
Thrombocytopenia grade 3 occurred in 43.5% of the patients and after 9.5% of the Local rash at the injection site was common and was reported for 8 patients (35%).
All adverse events are shown in Table 2 . All but one patient stopped azacytidine because of relapse. This patient had a thrombosis in the optic artery and lost vision in this eye. 
CR duration
Median CR duration for the 23 azacytidine treated patients was 13.5 months (2-49+).
Four patients (17%), without any obvious unifying characteristics, had a CR lasting for more than 24 months and two patients were still in CR at the last follow up. The study was not powered for subgroup analysis, however, no obvious differences in CR duration or survival were observed according to age or pre-induction diagnosis or cytogenetic subgroup (Figure 2 ). Pre-treatment platelet count below median was the A secondary objective of this study was to evaluate whether promoter methylation of selected genes could predict response to azacytidine. Eight of 9 patients with promoter methylation of any of the analyzed genes became unmethylated in CR. P15 methylation status prior to induction chemotherapy did not correspond to CR duration (P=0.82). Only 2 of 15 patients with pre-treatment CDH methylation reached CR and they both had very short CR durations (2.5 and 6 months, respectively). One patient developed P15 methylation in the bone marrow sampled at 12 months after CR and relapsed shortly after, at 15.5 months. Figure 3 shows methylation status and relapse information for all patients.
Overall survival
Median overall survival (OS) for the 23 patients who received maintenance treatment was 20.0 months (4-52+) (Figure 4 ). Two year survival was 37.5% and 13.9%, in expression and platelet counts below median were associated with shorter survival (P=0.04, 0.018 and 0.006 respectively) (Figure 4 ). There was no significant association between IPSS cytogenetic subgroup and survival.
Discussion
Prolonged therapy with azacytidine was recently shown to significantly improve survival and time to AML transformation in Intermediate-2 and high-risk MDS patients, according to a large randomized phase III trial, data that recently led to the approval of the drug by EMEA and that are likely to influence the European guidelines for treatment of this patient category (Fenaux et al, 2009) . However, when the present study was designed in 2002 primary therapy for high-risk and transformed MDS in most parts of Northern Europe was moderate intensity induction chemotherapy or supportive care only. There is overwhelming evidence that disease recurs in the vast majority of patients achieving a complete remission unless allogeneic stem cell transplantation is performed. Most patients relapse within the first year, and conventional consolidation chemotherapy does not seem to prolong CR duration (Hast el al, 2003; Ganser et al, 2000; Hofmann et al, 2007; Wattel et al, 1997; Kantarjian et al, 2006) . If there is a potential benefit from autologous stem cell This trial is the first to evaluate safety and feasibility of maintenance treatment with azacytidine for patients with high-risk MDS and MDS-AML with CR after induction chemotherapy. The hypothesis was that azacytidine maintenance could prolong time to relapse and that the results might constitute a basis for a prospective randomized phase III trial.
Azacytidine treatment was well tolerated at a starting dose of 60 mg /m 2 5/28 days, while higher doses, administered within 28 days from complete remission, induced high degree of grade 3 or 4 neutropenia. Also at the lower starting dose, the most common adverse event was grade 3 neutropenia and/or thrombocytopenia.
Interestingly, azacytidine treatment rarely induced anaemia and in fact more than two thirds of the patients experienced an improvement in haemoglobin levels during the first months of treatment (Fig 1) . As thrombocytopenia and neutropenia was common, this may not just reflect bone marrow recovery after induction chemotherapy but a positive direct effect of azacytidine on erythropoiesis. Other side effects were mild and manageable and only one patient stopped treatment due to side effects.
CR duration of 13.5 months and an overall survival of 20.0 months is not clearly different from previous studies on induction chemotherapy for patients with high-risk MDS or MDS-AML; however the majority of these studies included slightly younger patients (Hast et al, 2002; Ganser et al, 2000; Kantarjian et al, 2006; Hofmann et al, 2007; Wattel et al, 1997) . Studies on older patients with AML by the SWOG and the HOVON groups, including both de novo cases and secondary AML have shown overall survivals of 9 and 10 months respectively (Anderson et al, 2002; van der Holt et al, 2007) . Clearly however, azacytidine did not seem to prevent relapses in the majority of the cases.
The question that remains to be investigated is whether relapse was delayed in a subset of patients. This present study was not powered to analyze subgroups.
However, we conclude that there were no obvious differences in CR duration or overall survival with regard to age, diagnosis or cytogenetic subgroup, i.e.
parameters that in other studies have appeared as prognostic markers for outcome (Ganser et al, 2000; Wattel et al, 1997; Kantarjian et al, 2006) 
2009). Whether immunomodulation, by demethylation or not, may explain the
better overall outcome in this group remains to be studied. As previously reported by us, methylation of CDH or of multiple genes was associated with a poor response to induction chemotherapy (P=0.008) (Grövdal et al, 2007) . Hence, very few patients with any other gene than P15 methylated actually reached CR and, accordingly, most of these patients never started azacytidine maintenance. In the whole study population, CDH methylation was related to significantly shorter survival (P=0.003). The only two patients with CDH methylation subjected to azacytidine maintenance relapsed early, after 2.5 and 6 months. This strengthens our previous observation that CDH methylation is a marker for poor overall prognosis and poor response to induction chemotherapy. Interestingly, methylation status of P15 was not correlated to CR duration or survival, which contradicts previous reports that P15 methylation predicts a worse outcome (Aggerholm et al, 2006; Christiansen et al, 2003) . Whether this reflects a selection bias, i.e. P15 methylation will not add further to the risk profile in a cohort with a high proportion of other high-risk features and confirmed AML transformation, or if it may indicate that azacytidine maintenance actually counteracted the negative effect of P15 methylation remains to be investigated. At this stage we can only conclude that methylation analysis of any of the three selected genes cannot be used to select patients for maintenance treatment with azacytidine. Dose reduction of azacytidine was allowed to maintain dose interval and to avoid potentially hospitalizing adverse events in this elderly patient group. Hence, insufficient azacytidine doses might have influenced the overall results. However, patients treated with doses above or below the median dose showed no differences with regard to any of the measured outcomes.
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